PER Podcast Sessions Podcast Por PER® Spectives arte de portada

PER Podcast Sessions

PER Podcast Sessions

De: PER® Spectives
Escúchala gratis

Acerca de esta escucha

 Physicians' Education Resource® (PER®) is committed to advancing patient care through professional education. This podcast is a natural extension of PER®'s efforts to provide medical education for health care providers to stay up to date with advances in medical care, from diagnosis through treatment, with the ultimate goal of improving patient outcomes. Visit www.gotoper.com for more information.Copyright ©2019, Physicians' Education Resource®, LLC., All rights reserved Ciencia Ciencias Biológicas
Episodios
  • S2 Ep34: PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

    S2 Ep34: PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)
    Jun 23 2025
    Episode Description

    In this podcast, ALS expert Terry Heiman-Patterson, MD, discusses best practices for ALS diagnosis and use of targeted therapy.

    Learning Objectives

    Upon successful completion of this activity, you should be better prepared to:

    • Apply recommended diagnostic criteria and strategies to make an early, accurate diagnosis of ALS
    • Discuss the mechanisms of action, efficacy, and safety of approved and emerging treatments for patients with ALS

    Acknowledgment of Educational Grant Support

    This activity is supported by an educational grant from Mitsubishi Tanabe Pharma America.

    Accreditation/Credit Designation

    Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 0.5 Contact Hours.

    Instructions on How to Receive Credit

    1. Listen to this podcast in its entirety.
    2. Go to gotoper.com/credit and enter code: XXXX
    3. Answer the evaluation questions.
    4. Request credit using the drop-down menu.
    You may immediately download your certificate.
    Chair:

    Terry Heiman-Patterson, MD

    Professor, Neurology, Lewis Katz School of Medicine at Temple University
    Director, Temple MDA/ALS Center of Hope
    Philadelphia, PA

    Faculty, Staff, and Planners’ Disclosures

    In accordance with ACCME Guidelines, PER® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

    The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.

    This podcast was developed by PER® editorial staff based on an online activity developed with these faculty.

    Release Date

    June 30, 2025
    Expiration Date

    Jun 30, 2026

    Off-Label Disclosure and Disclaimer

    This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
    Más Menos
    26 m
  • S2 Ep33: PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

    S2 Ep33: PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)
    Jun 23 2025
    Episode Description

    In this podcast, ALS expert clinician-researcher Richard Bedlack MD, PhD, discusses targeted therapy for ALS and the role of individualized, multidisciplinary care to optimize patient outcomes.

    Learning Objectives

    Upon successful completion of this activity, you should be better prepared to:

    • Discuss the mechanisms of action, efficacy, and safety of approved and emerging treatments for patients with ALS
    • Develop individualized, multidisciplinary ALS management plans in collaboration with the patient and caregiver
    Acknowledgment of Educational Grant Support

    This activity is supported by an educational grant from Mitsubishi Tanabe Pharma America.

    Accreditation/Credit Designation

    Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 0.5 Contact Hours.

    Instructions on How to Receive Credit

    1. Listen to this podcast in its entirety.
    2. Go to gotoper.com/credit and enter code: XXXX
    3. Answer the evaluation questions.
    4. Request credit using the drop-down menu.

    You may immediately download your certificate.

    Chair:

    Richard Bedlack, MD, PhD

    Stewart, Hughes, and Wendt Distinguished Professor
    Director of ALS Program
    Duke University Department of Neurology
    Durham, NC

    Disclosures: Consultant: AB Science, Advarra, ALS Association, Amylyx, Biogen Idec, Capvision, CareSpace Health, ClearView, Compassionate Care ALS, Eikonoklastes, Guidepoint Global, Health Advances, Health Care Strategy Partners, Ionis Pharmaceuticals, Kaplan, KeyQuest, Med-IQ, NeuroSense, Novartis, Prime Education, PTC Therapeutics, Roon; Research Support: Healey Center, MediciNova; Advisory Board: GenieUs; Other: Biogen, Ionis, NeuroSense, PTC.
    Faculty, Staff, and Planners’ Disclosures
    In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

    The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.

    This podcast was developed by PER® editorial staff based on an online activity developed with these faculty.
    Release Date

    June 30, 2025

    Expiration Date

    June 30, 2026

    Off-Label Disclosure and Disclaimer

    This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
    Más Menos
    25 m
  • S2 Ep32: Breaking Barriers in HER2-Mutant NSCLC: Exploring the Promise of Next-Generation TKIs

    S2 Ep32: Breaking Barriers in HER2-Mutant NSCLC: Exploring the Promise of Next-Generation TKIs
    Jun 20 2025
    Episode Description
    In this episode of the PER® podcast, we explore the evolving landscape of HER2-mutant non–small cell lung cancer (NSCLC)—a rare and historically difficult-to-treat subset of lung cancer. Join Millie Das, MD, from Stanford/VA Palo Alto; and Eric Kumar Singhi, MD, from The University of Texas MD Anderson Cancer Center; as they delve into emerging clinical data on next-generation, HER2-selective tyrosine kinase inhibitors. Through expert insights and discussion of recent trial findings, this conversation highlights how novel targeted therapies are reshaping treatment strategies and providing new hope for patients with HER2-mutant NSCLC.

    Acknowledgment of Educational Grant Support
    This activity is supported by educational grants from AstraZeneca Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc; Catalyst Pharmaceuticals, Inc; Daiichi Sankyo, Inc; Exact Sciences Corporation; Janssen Biotech, Inc; and Partner Therapeutics, Inc.

    Accreditation/Credit Designation

    Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.

    Instructions on How to Receive Credit
    1. Listen to this podcast in its entirety.
    2. Go to gotoper.com/credit and enter code: 3462
    3. Answer the evaluation questions.
    4. Request credit using the drop-down menu.

    You may immediately download your certificate.

    Today’s faculty are:

    Millie Das, MD
    Chief, Oncology, VA Palo Alto Health Care System
    Clinical Professor, Stanford University
    Palo Alto, CA

    Disclosures: Grant/Research Support: CellSight, Genentech, Merck, Novartis, Varian; Consultant: AbbVie, Amgen (uncompensated), Bristol Myers Squibb, Catalyst, Daiichi Sankyo, EMD Serono, Genentech (uncompensated), Gilead, Guardant, Janssen, Merus, Natera, Novocure, Regeneron, Sanofi/Genzyme.

    Eric K. Singhi, MD
    Assistant Professor
    Department of General Oncology and Thoracic/Head and Neck Medical Oncology
    The University of Texas MD Anderson Cancer Center
    Houston, TX

    Disclosures: Advisory Board: AbbVie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Caris Life Sciences, Janssen, Lilly, Novocure, Regeneron.

    The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.

    PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

    Off-Label Disclosure and Disclaimer
    This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

    Release Date
    June 20, 2025

    Expiration Date
    June 20, 2026
    Más Menos
    26 m
adbl_web_global_use_to_activate_webcro805_stickypopup
Todavía no hay opiniones